Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose
To Mojsov, this seemed particularly promising
The authors found that existing research had shown that individuals using exenatide (brand name Byetta) another GLP-1 analogue had decreased neuronal responses to pictures of food in parts of the brain regulating appetite and reward
Similarly, drugs from the class of aromatase inhibitors (AIs), including letrozole, anastrozole, and exemestane, have also shown positive results in postmenopausal women (214)
100 mM KC1